Antibiotic distribution and recovery in tissue
Project factsheets
Learn more about the projects supported by IHI as well as the Innovative Medicines Initiative (IMI).
Displaying 55 projects/programmes
Accelerated development of vaccine benefit-risk collaboration in Europe
Antimicrobial Resistance Accelerator
Biomarkers for Enhanced Vaccine Immunosafety
Corona accelerated R&D in Europe
Combatting Bacterial Resistance in Europe - Carbapenem Resistance
Combatting Bacterial Resistance in Europe - Clostridium Difficile Infections
Combatting bacterial resistance in Europe - molecules against Gram negative infections
Combatting Bacterial Resistance in Europe
Collaboration for prevention and treatment of MDR bacterial infections
COVID-19 infections - remote early detection
A minituarized disposable molecular diagnostics platform for combatting coronavirus infections
Rapid and secure AI imaging based diagnosis, stratification, follow-up, and preparedness for coronavirus pandemics
Development of Robust and Innovative Vaccine Effectiveness
Driving re-investment in R&D and responsible antibiotic use
Communication strategy and tools for optimizing the impact of Ebola vaccination deployment
Ebola and other filoviral haemorrhagic fevers
Ebola virus: modern approaches for developing bedside rapid diagnostics
Manufacturing and development for rapid access Ebola vaccine
Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen
Development of a prophylactic Ebola vaccine using an heterologous prime-boost regimen: phase II
Bringing a prophylactic Ebola vaccine to licensure
European Gram-negative Antibacterial Engine
European regimen accelerator for tuberculosis
EU patient-centric clinical trial platform
Ultra-fast molecular filovirus diagnostics
Standardization and development of assays for assessment of influenza vaccines correlates of protection
Novel Gram-negative antibiotic now
Inhaled antibiotics in bronchiectasis and cystic fibrosis
Development of Impentri, an intravenous imatinib formulation for COVID-19 acute respiratory distress syndrome (ARDS)
Innovations to accelerate vaccine development and manufacture
Evaluation of a production ready portable, point-of-need platform (instrument and reagents), direct from nasal swab test for the molecular diagnostic detection of COVID-19 infection
Modern approaches for developing antivirals against SARS-CoV 2
Mobile Filovirus Nucleic Acid Test
New Drugs for Bad Bugs
PERtussIS COrrelates of Protection Europe
Pan Ebola vaccine innovative approach
Model-based preclinical development of anti-tuberculosis drug combinations
Predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance
Preparing for RSV immunisation and surveillance in Europe
Robust automation and point of care identification of COVID
Development of rapid point-of-care test platforms for infectious diseases
Respiratory syncytial virus consortium in Europe
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Molecular basis of the bacterial cell wall permeability
Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments
Academia and industry united innovation and treatment for tuberculosis
Vaccine lot to vaccine lot comparison by consistency testing
The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
Viral haemorrhagic fever: modern approaches for developing bedside rapid diagnostics
Vaccines and infectious diseases in the ageing population
Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV
Vaccine safety and immunogenicity signatures of human responses to VSV-ZEBOV
Zoonotic anticipation and preparedness initiative
